Finance

Lists
Q3 2026 earnings • released • EPS miss -3.13%
See results
IMUX:NASDAQ
Immunic Inc
$7.52
-3.47%
(-0.27) 1D
$7.60
+1.06% (+0.080)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMUX...
Open
$7.87
High
$7.87
Low
$7.52
Mkt. cap
102.61M
Avg. vol.
339.08K
Volume
105.53K
52-wk high
$17.43
52-wk low
$5.06
EPS
-$4.20
Beta
1.49
Shares outstanding
13.64M
No. of employees
100
Open
$7.87
High
$7.87
Low
$7.52
Mkt. cap
102.61M
Avg. vol.
339.08K
Volume
105.53K
52-wk high
$17.43
52-wk low
$5.06
EPS
-$4.20
Beta
1.49
Shares outstanding
13.64M
No. of employees
100
News stories
From web sources and news partners
About Immunic Inc
CEODaniel Vitt
Employees100
FoundedMay 2003
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteimux.com
Analyst ratings
Based on 10 analysts giving stock ratings to IMUX in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for IMUX in the last 3 months.
Highest
Current $7.52
$70.00 (+830.85%)
Average
$38.00 (+405.32%)
Lowest
$22.00 (+192.55%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yatin Suneja
Guggenheim
Buy
Reiterated
$70.00
+830.9%
11/09/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$22.00
+192.6%
11/06/2026
Martin Fan
Wedbush
Buy
Maintained
$45.00
+498.4%
11/06/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$25.00
+232.4%
10/30/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
$30.00
+298.9%
10/23/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$56.00
+644.7%
09/11/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
-
-
09/10/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/10/2026
William Wood
B. Riley Securities
Buy
Maintained
$27.00
+259%
09/02/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
$29.00
+285.6%
09/01/2026
Rudy Li
Wolfe Research
Buy
Reiterated
$25.00
+232.4%
08/11/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
04/15/2026
Last report
Nov 13, 2026
Fiscal period
Q3 2026
-$0.99 / -$0.96
-3.13%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20.01M
19.07M
25.63M
25.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.98M
4.26M
7.61M
9.40M
Operating expense
25.99M
23.33M
33.24M
35.33M
Total operating expenses
25.99M
23.33M
33.24M
35.33M
Operating income
-25.99M
-23.33M
-33.24M
-35.33M
Other non operating income
-5.00K
5.53M
-113.00K
-58.00K
EBT including unusual items
-25.58M
-19.30M
-32.59M
-34.10M
EBT excluding unusual items
-25.58M
-17.60M
-32.59M
-34.10M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25.58M
-19.30M
-32.59M
-34.10M
Net profit margin
-
-
-
-
Earnings per share
-1.30
-0.70
-1.08
-0.80
Interest and investment income
419.00K
197.00K
760.00K
1.29M
Interest expense
-
-
-
-
Net interest expenses
419.00K
197.00K
760.00K
1.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.95M
-23.28M
-33.20M
-35.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps